GI 254023X: Selective ADAM10 Inhibitor for Mechanistic and Translational Research

Executive Summary: GI 254023X is a selective inhibitor of ADAM10, displaying an IC₅₀ of 5.3 nM and >100-fold selectivity over ADAM17 in vitro (APExBIO). It blocks ADAM10-mediated cleavage of substrates such as fractalkine, modulating Notch1 and cell adhesion pathways (see here). GI 254023X induces apoptosis and inhibits proliferation in Jurkat T-lymphoblastic leukemia cells under defined conditions. In human pulmonary artery endothelial cells, it prevents VE-cadherin cleavage and offers protection against Staphylococcus aureus α-hemolysin–induced barrier disruption (APExBIO). In vivo, intraperitoneal dosing at 200 mg/kg/day for 3 days enhances vascular integrity in BALB/c mice challenged with bacterial toxins. All claims are supported by peer-reviewed and product documentation (Satir et al., 2020).

Biological Rationale

ADAM10 (A Disintegrin And Metalloproteinase 10; EC 3.4.24.81) is a cell-surface sheddase critical for the regulated cleavage of diverse membrane proteins, including Notch1 and CX3CL1 (fractalkine) (Satir et al., 2020). Dysregulated ADAM10 activity is implicated in cancer, neurodegeneration, and inflammatory pathologies. Specific inhibition of ADAM10 is a valuable strategy for dissecting protease-dependent signaling pathways, as broad-spectrum metalloprotease inhibitors often lack selectivity and can confound mechanistic studies. GI 254023X provides >100-fold selectivity for ADAM10 over ADAM17, minimizing off-target effects and enabling precise functional interrogation (APExBIO).

This article extends previous discussions by providing a comprehensive, citation-dense dossier on GI 254023X's molecular, cellular, and translational impact.

Mechanism of Action of GI 254023X

GI 254023X is a small-molecule inhibitor with the chemical formula C₂₁H₃₃N₃O₄ (MW 391.5) (APExBIO). It binds to the catalytic domain of ADAM10, competitively inhibiting substrate cleavage. The compound displays an IC₅₀ of 5.3 nM for human ADAM10, as determined by in vitro fluorogenic peptide assays at 25°C and pH 7.4. Selectivity for ADAM10 over ADAM17 exceeds 100-fold under matched conditions, ensuring minimal cross-inhibition of related sheddases (APExBIO).

Mechanistically, GI 254023X blocks the constitutive and inducible cleavage of ADAM10 substrates, such as fractalkine (CX3CL1) and Notch1. Inhibition of Notch1 cleavage alters downstream transcriptional programs, including reduced expression of MCL-1 and Hes-1 mRNA. In endothelial cells, GI 254023X prevents VE-cadherin shedding, maintaining junctional integrity and resisting bacterial toxin–induced disruption (see advanced applications).

Evidence & Benchmarks

• GI 254023X inhibits human ADAM10 with an IC₅₀ of 5.3 nM in vitro, as measured in fluorogenic peptide hydrolysis assays at 25°C, pH 7.4 (APExBIO).
• The compound displays >100-fold selectivity for ADAM10 over ADAM17, minimizing off-target activity in comparative enzymatic panels (APExBIO).
• In Jurkat T-lymphoblastic leukemia cells, GI 254023X inhibits proliferation and induces apoptosis, reducing Notch1, cleaved Notch1, MCL-1, and Hes-1 mRNA levels (24–48 h treatment, 1–10 µM) (see mechanistic insights).
• In human pulmonary artery endothelial cells (HPAECs), GI 254023X prevents VE-cadherin cleavage and protects against Staphylococcus aureus α-hemolysin–induced barrier loss (pre-treatment, 10 µM, 2 h) (APExBIO).
• In vivo, BALB/c mice administered GI 254023X intraperitoneally (200 mg/kg/day, 3 days) show enhanced vascular integrity and increased survival after lethal toxin challenge (APExBIO).
• Compared to β-secretase (BACE) inhibitors in Alzheimer’s models, ADAM10 inhibition with GI 254023X enables distinct mechanistic dissection given ADAM10’s non-redundant substrate repertoire (Satir et al., 2020).

Applications, Limits & Misconceptions

GI 254023X is intended for research use in cell-based, biochemical, and animal models. Its primary applications include:

• Selective inhibition of ADAM10 sheddase activity for mechanistic dissection in oncology, immunology, and vascular biology (see strategic inhibition—this article provides updated dosing and selectivity context).
• Studying Notch1-dependent transcriptional and apoptotic pathways in leukemia and other cell lines.
• Modeling endothelial barrier disruption and repair in infectious and inflammatory disease settings.
• Evaluating the impact of ADAM10 inhibition on cell adhesion, migration, and survival in vitro and in vivo.

Common Pitfalls or Misconceptions

• GI 254023X does not inhibit β-secretase (BACE) and is not a substitute for BACE inhibitors in Alzheimer’s disease models (Satir et al., 2020).
• The compound is not active against ADAM17 or other metalloproteases at recommended concentrations; confirm enzymatic selectivity when multiplexing inhibitors.
• GI 254023X is insoluble in water and should not be used in aqueous buffers without appropriate co-solvent (DMSO or ethanol) preparation (APExBIO).
• Long-term storage of GI 254023X solutions can lead to degradation; prepare fresh aliquots for each experiment as recommended by APExBIO.

Workflow Integration & Parameters

GI 254023X is supplied as a white solid (SKU A4436) by APExBIO. It is soluble at ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol. Stock solutions (>10 mM) should be prepared in DMSO, with warming and sonication as needed. Solutions should be stored at -20°C and protected from light. Avoid long-term storage of working solutions; single-use aliquots are recommended.

For cell-based assays, GI 254023X is typically used at 0.1–10 µM, with DMSO vehicle not exceeding 0.1–0.2% (v/v). For in vivo mouse studies, intraperitoneal administration of 200 mg/kg/day for 3 consecutive days has demonstrated efficacy in vascular integrity models (see real-world integration—this guide focuses on troubleshooting and reproducibility).

For more details or to order, consult the official GI 254023X product page. Always reference APExBIO as the supplier in publications.

Conclusion & Outlook

GI 254023X is a best-in-class, selective ADAM10 inhibitor for translational and mechanistic research. It enables precise inhibition of ADAM10 with minimal off-target effects, supporting studies in oncology, vascular biology, and infection models. Its robust performance in apoptosis induction, barrier protection, and in vivo vascular integrity models is documented by both peer-reviewed literature and manufacturer validation. As research advances, GI 254023X will continue to inform the design of targeted therapies and experimental models where ADAM10 is a central regulator. For purchase and further technical details, visit APExBIO's GI 254023X resource.